Overview of Levo 500

Levo 500 is the trade name for a pharmaceutical product whose active substance is Levofloxacin, a purely synthetic compound used to treat serious bacterial infections. This medicine is primarily available for oral administration as a film-coated tablet and belongs to the powerful fluoroquinolone antibiotic class.

Property	Description
Active ingredient	Levofloxacin
Form	Film-coated tablet or Solution for intravenous infusion
Pharmacological class	Fluoroquinolone antibiotic
Common purpose	Anti-infective agent
Origin	Synthetic L-isomer

What Type of Medicine is Levo 500?

Levo 500 is a prescription-only synthetic antibacterial agent belonging to the fluoroquinolone drug class. The active substance, Levofloxacin, is chemically the L-isomer of the older compound Ofloxacin, a structural distinction which enhances its antimicrobial activity. This classification means it is one of the synthetic broad-spectrum quinolone agents designed to eliminate a wide variety of harmful bacteria.

Levofloxacin is formally recognized as a single-entity product and its pharmacological properties are characterized by its identity as a synthetic compound utilized specifically for systemic anti-infective therapy.

The Role of Levofloxacin as an Anti-infective Agent

The primary purpose of Levo 500 is to function as a potent anti-infective agent to eliminate bacterial pathogens. It achieves this through a powerful bactericidal action, meaning it actively kills the harmful bacteria rather than just inhibiting their growth. This mechanism is clinically recognized for its efficacy against common bacterial targets.

This bactericidal mechanism involves directly interfering with the bacteria’s DNA replication process by inhibiting the necessary enzymes DNA gyrase and topoisomerase IV. Levofloxacin is utilized for its effective antibacterial spectrum, which provides definitive eradication of susceptible bacteria.

Understanding the 500 mg Tablet and its Form

The designation Levo 500 most frequently refers to the 500 mg strength of the Levofloxacin film-coated tablet intended for oral administration. This form allows the antibacterial agent to be absorbed and distributed systemically via the bloodstream.

While the oral tablet is the most common form, Levofloxacin is also formulated as a sterile aqueous solution for intravenous administration, reflecting its versatile use across both hospital and outpatient settings.

Regulatory References

National Institutes of Health (NIH) confirms

What side effects are possible with Levo 500?

Levofloxacin, the active substance in Levo 500, has an officially documented safety profile characterized by a range of adverse reactions, which government regulators classify by frequency and the body system affected. Common reactions (in ge 1/100 patients) primarily involve the gastrointestinal and nervous systems, including nausea, headache, diarrhoea, insomnia, and dizziness. Increases in liver enzymes have also been reported as common.

Documented Serious Adverse Reactions

Official labeling highlights the potential for disabling and potentially irreversible serious adverse reactions affecting multiple systems, including the tendons, peripheral nervous system, and central nervous system [FDA].

Adverse Reaction Type	Safety Implication	Onset Timing
Musculoskeletal	Tendinitis, Tendon Rupture (most often Achilles tendon)	Can occur within 48 hours or up to several months after discontinuation
Neurological	Peripheral Neuropathy (tingling, numbness, pain) and CNS effects (e.g., psychosis, convulsions, suicidal ideation)	Can occur within hours to weeks after starting treatment
Cardiovascular	Risk of QT prolongation leading to Torsade de pointes; increased risk of Aortic Aneurysm and Dissection	General risk factor concern

Population-Specific Safety Constraints

The risk of tendon disorders is increased in older adults (ge 60 years), patients with renal impairment, and those concurrently receiving corticosteroids [GOV.UK]. The medicine is explicitly contraindicated in patients with a history of epilepsy or tendon disorders related to previous fluoroquinolone use. Use is generally avoided in patients with Myasthenia Gravis due to the potential for muscle weakness exacerbation [FDA].

Overdose and Emergency Response

Overdose and when to seek help

The following information is strictly based on official government regulatory documents and describes the known overdose profile of Levo 500 (levofloxacin).

Documented Overdose Presentations

Acute overdose with levofloxacin has been reported to involve severe symptoms affecting the Central Nervous System (CNS) and the Gastrointestinal (GI) system. The most prominent signs and symptoms that characterize an overdose include severe dizziness, profound drowsiness, disorientation, and slurred speech. Gastrointestinal symptoms like nausea and vomiting are also commonly reported in these situations. Overdoses have involved the ingestion of large amounts of levofloxacin, leading to these acute toxic effects.

Required Emergency Action

If a Levo 500 overdose is suspected or if too much of the medication has been taken, immediate and urgent professional medical attention is required. You must seek emergency medical attention or contact a Poison Help line immediately, even if the person experiences no symptoms. The official regulatory guidance stresses the need for prompt action to ensure appropriate medical management and supportive measures. Do not wait for symptoms to develop before seeking help.

Therapeutic Uses of Levo 500

The medicine is considered relevant in conditions characterized by periods of heightened symptoms, including those affecting the respiratory tract, urogenital system, and skin and soft tissue.

It is relevant for managing symptomatic discomfort in acute or recurrent conditions, such as those involving the lungs, kidneys, prostate, or deep layers of the skin.

“The approach focuses on easing symptoms that create noticeable physiological strain, and contributes to improved comfort during periods of heightened symptoms.”

Supportive Management for Symptomatic Discomfort

This medicine is applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms in the airways, urinary tract, and skin. It helps address symptom clusters that may become intense or disruptive and are related to inflammatory or irritative states. By providing short-term symptomatic assistance, this use assists with maintaining functional stability and may help patients cope more steadily with difficult episodes.

Quick Fact: Supportive Relief for Systemic Symptoms The medication may assist with managing symptoms related to systemic imbalance, such as high fever and malaise, that often accompany acute or disruptive episodes.

Eligibility and Restrictions for Use

The eligibility for Levo 500 is strictly defined by government regulatory standards. The medicine is contraindicated and must not be used by individuals with a history of hypersensitivity to Levofloxacin or any other quinolone antibacterial agent. Use is also officially prohibited in patients with a history of tendon disorders linked to prior fluoroquinolone exposure, as well as those with epilepsy or uncorrected heart rhythm conditions such as known QT interval prolongation. Patients with a history of Myasthenia Gravis are also restricted from using the medicine.

For Age-Related Eligibility, Levofloxacin is generally contraindicated for children and adolescents under 18 years, except where regulatory agencies have permitted use for specific, life-threatening public health conditions. Pregnant and breastfeeding women are officially excluded from using the medication.

Conditional eligibility applies to certain populations. Individuals with renal impairment are eligible for use only under restricted conditions, as the official prescribing information mandates dosage modification. Increased caution is required for older adults and patients with diabetes mellitus or those concurrently receiving corticosteroid therapy, as these conditions carry specific, officially documented usage constraints.

What should I know about interactions with other medicines?

Levo 500 (levofloxacin) has documented interactions with several categories of medicinal products and substances, primarily affecting its absorption or enhancing the effect of the interacting drug.

Reduced Absorption

Oral levofloxacin absorption is significantly reduced when taken concomitantly with multivalent cation-containing products due to chelation. These include antacids (containing magnesium or aluminum), sucralfate, iron salts, zinc salts, and buffered formulations of didanosine. To minimize this interaction, levofloxacin tablets should not be taken within two hours before or two hours after administration of these products.

Increased Systemic Effects

Warfarin: Concomitant use with levofloxacin can enhance the anticoagulant effect of warfarin (a Vitamin K antagonist), increasing the risk of bleeding. Close monitoring of Prothrombin Time and INR is necessary. The mechanism involves an effect on warfarin's metabolism and potentially the gut flora that produce Vitamin K.
Antidiabetic Agents: Combining levofloxacin with insulin or oral hypoglycemic agents may lead to disturbances in blood glucose levels, including hypoglycemia and hyperglycemia, requiring careful blood glucose monitoring.
QT-prolonging Drugs: Levofloxacin can prolong the QT interval; therefore, co-administration with other medicines that prolong the QT interval (e.g., certain antiarrhythmics or antipsychotics) should be avoided due to the risk of additive effects.
Corticosteroids: The concurrent use of levofloxacin and corticosteroid drugs increases the risk of tendinitis and tendon rupture, a risk particularly heightened in older adults.
NSAIDs and Theophylline: Use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or theophylline may increase the risk of central nervous system stimulation and seizures.
Probenecid and Cimetidine: These agents decrease the renal clearance of levofloxacin, potentially leading to higher systemic exposure.

Mechanism of Action

️ How Levo 500 Works: Mechanism of Action

Levo 500's primary mechanism involves its action as an inhibitor targeting the essential genetic machinery within susceptible bacteria. This process results in a rapid bactericidal effect—meaning it actively kills susceptible bacteria.

Levofloxacin exerts its effect by binding to and inhibiting two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are crucial for untangling, unwinding, and repairing the bacterial DNA strands required for cell division and function. The drug works by trapping the enzymes onto the bacterial DNA after they have cleaved it, thereby preventing the necessary re-ligation step.

The irreversible stabilization of the lethal enzyme-DNA complex leads to the rapid and cumulative accumulation of double-strand DNA breaks throughout the bacterial genome. This extensive, irreparable damage triggers a fatal bacterial stress response, which swiftly leads to the cell death of the pathogen. This destructive molecular cascade is the physiological basis for the drug's bactericidal action against susceptible cells.

The biological functional capacity of this mechanism can be limited by evolutionary changes in the target pathogen. For instance, genetic mutations in the target enzymes can reduce the drug's binding affinity, or the bacteria may overexpress efflux pumps that actively expel the molecule from the cell, thus weakening the expected bactericidal effect.

Dosage and Administration Information

Levo 500 is administered systemically through two official routes: oral (using film-coated tablets or an oral solution) and intravenous (IV) infusion. The IV and oral forms are generally considered interchangeable for sequential therapy due to the drug’s high oral absorption.

The standard adult dosing regimen is typically once every 24 hours, with the dose prescribed at 250 mg, 500 mg, or 750 mg based on the required course duration. Duration is indication-dependent, ranging from a 3 day course for uncomplicated conditions to an extended 60 day plan for specific prophylaxis. Pediatric dosing for certain conditions is weight-based (8 mg/kg) and administered every 12 hours for patients under 50 kg.

The administration schedule mandates strict rules: while tablets can be taken without regard to food, the oral solution requires separation from meals by at least one hour before or two hours after. Specific procedural conditions are required for the IV route, where the infusion must be slow, administered over 60 minutes for lower doses or 90 minutes for the 750 mg dose; rapid IV injection is prohibited. For all oral forms, administration with multivalent cation products (e.g., antacids) must be separated by a 2 hour interval. Dosage adjustments are mandatory for adults with renal impairment, specifically those with a Creatinine Clearance (CrCl) below 50 mL/min, which necessitates a reduced dose or extended dosing interval.

Recent Clinical Evidence

Research evidence / Overview of studies for Levo 500

The available evidence for Levofloxacin (Levo 500) has been collected through a substantial number of formal clinical trials, including Randomized Controlled Trials (RCTs) and systematic reviews, which has been reviewed by regulatory authorities. Research has examined its application in conditions characterized by periods of heightened symptom activity in the respiratory, urogenital, and skin systems. Studies help show what has been observed so far, focusing on group patterns rather than individual predictions.

Evidence from Studies on Serious Respiratory Infections

Research has explored the use of Levofloxacin in studies concerning significant respiratory conditions, such as Community-Acquired Pneumonia (CAP). These studies primarily involved adults and often used comparative trial designs, where the medicine was studied against another established antibiotic. Research focused on tracking key outcomes related to systemic or functional imbalance, such as fever resolution and the elimination of the specific bacteria causing the infection (microbiological eradication).

Evidence for conditions like Acute Bacterial Sinusitis (ABS) and Acute Exacerbation of Chronic Bronchitis (ABECB) also exists. However, the regulatory interpretation of this evidence highlights a key limitation: the research findings and overall risk-benefit profile have led government health authorities to restrict the medicine’s use for these conditions. The regulatory restrictions mean that the research data applies primarily to situations where alternative treatments are not an option.

Evidence from Studies on Urinary Tract and Prostate Infections

Levofloxacin was evaluated in studies for complex infections of the urinary tract (cUTI) and kidneys (Acute Pyelonephritis). Findings describe patterns observed in the studies, where both oral and intravenous forms yielded measurements of pathogen eradication. Research also explored the use of Levofloxacin for Chronic Bacterial Prostatitis, which involved longer treatment durations—typically 28 days. These studies monitored outcomes related to functional imbalance and included follow-up periods to track recurrence patterns.

Evidence Consistency, Regulatory Context, and Uncertainty

While the evidence landscape includes multiple RCTs and generally shows consistent patterns related to microbiological eradication, the overall scientific conclusion is qualified by its safety profile. The regulatory authorities have indicated that for several common conditions, the risk profile warrants the medicine being reserved for patients with no acceptable treatment alternatives. This context means that evidence quality varies across studies, and certainty remains low for its routine application in mild-to-moderate infections. Research does not provide individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References NIH Bookshelf: Levofloxacin Classification and Overview

Frequently Asked Questions (FAQ)

Common questions about Levo 500 (FAQ)

Q: How long does Levo 500 stay in your system after stopping it?

According to official pharmacokinetics data, Levo 500 is primarily eliminated from the body by the kidneys. For an adult with normal kidney function, the average elimination half-life—the time it takes for half the drug to leave the body—is described as approximately 6 to 8 hours. This means that after about this time, half the medicine has left the body.

Q: Can Levo 500 be used for a cold or the flu?

Official drug information indicates that Levo 500 is an antibacterial agent, which means it is designed to kill susceptible bacteria. It is therefore not effective and is not intended for the treatment of infections caused by viruses, such as the common cold or influenza (the flu).

Q: Does Levo 500 interact with common pain relievers like Tylenol (acetaminophen)?

The formal drug interaction sections of the official product information do not typically list a specific interaction between levofloxacin and acetaminophen (Tylenol). However, official guidance emphasizes informing your healthcare provider about all medicines being taken.

Q: Should I avoid dairy products while taking Levo 500?

Yes, official patient information advises separating Levo 500 from dairy products like milk and yogurt. These products contain multivalent cations that can bind to the medicine and significantly reduce its absorption into the bloodstream. Official product information suggests separating the oral tablets or solution by at least 2 hours from consuming dairy.

Q: What is the difference between Levo 500 and Amoxicillin?

The primary difference lies in their chemical classifications and mechanisms of action. Levo 500 belongs to the Fluoroquinolone class, which kills bacteria by interfering with their DNA processes. In contrast, Amoxicillin belongs to the Penicillin class, which acts by disrupting the formation of the bacterial cell wall.

Q: What happens if I miss a scheduled time to take Levo 500?

Official patient information outlines a standard procedure for a missed dose. This procedure typically advises the use of the dose as soon as it is remembered unless it is nearly time for the next dose. It specifies that no more than one dose should be taken in a single day.

Q: Does Levo 500 have a Black Box Warning, and what does that mean?

Yes, the FDA drug label includes a Black Box Warning, which is the strongest caution required by the agency. This warning highlights the risk of serious and potentially irreversible side effects, specifically involving tendons, nerves, and the central nervous system. This warning serves to draw attention to the potential for these serious adverse reactions.

Q: How does Levo 500 affect the helpful bacteria in my body?

As a broad-spectrum antibiotic, Levo 500 is designed to eliminate a wide range of susceptible bacteria, including the harmful ones causing infection. This action can unintentionally disrupt the natural, beneficial balance of bacteria in the gut and other parts of the body. This disruption may sometimes lead to secondary conditions, such as C. difficile diarrhea or fungal infections.

Q: Will Levo 500 make birth control pills less effective?

Official drug interaction data does not consistently show that levofloxacin reduces the effectiveness of all oral contraceptives. Nevertheless, due to reports of potential interference, some experts advise patients to consider an alternative or additional method of birth control while undergoing treatment with Levo 500.

Q: Can I drive or operate machinery while using Levo 500?

The official product information advises caution when driving or operating machinery due to potential side effects like dizziness, lightheadedness, and visual disturbances. The official guidance indicates that caution should be exercised before engaging in these activities.

Q: What are the most common reasons people stop taking Levo 500 early?

Patients are instructed in regulatory documents to discontinue Levo 500 immediately and seek medical attention if they experience any signs of a serious adverse reaction. These reactions include pain or swelling that suggests a tendon problem, symptoms of nerve damage (peripheral neuropathy) like tingling or numbness, or signs of a severe allergic reaction.

Q: Is Levo 500 available over-the-counter in any country?

In the United States, Europe, and most other highly regulated health systems, levofloxacin is strictly a prescription-only medicine. Its status as prescription-only reflects the regulatory need for healthcare provider oversight.

Q: Is it true that Levo 500 can cause sun sensitivity?

Yes, the official labeling includes warnings regarding photosensitivity, meaning Levo 500 can make your skin unusually sensitive to sun exposure and UV light. Official information suggests limiting sun exposure, avoiding sunlamps or tanning beds, and wearing protective clothing when using this medicine.

Q: Can Levo 500 be crushed or cut in half?

Official administration guidelines generally instruct that the tablets should be swallowed whole with a glass of water. Modifying the tablet by crushing or cutting it may alter the drug's absorption rate. Any deviation from swallowing the tablet whole is generally performed only under medical direction.

Q: How is Levo 500 processed by the liver?

According to pharmacokinetic data, Levo 500 undergoes very little metabolism by the liver. The majority of the medicine is eliminated from the body in an unchanged form, primarily through the kidneys. Because of this, dosage adjustments are typically made based on kidney function rather than liver function.

Q: Can Levo 500 cause yeast infections?

Yes, official documents list the occurrence of fungal infections, such as oral candidiasis (oral fungal infection) and vulvovaginal mycotic infection (yeast infection), as uncommon side effects. These secondary infections may occur due to the antibiotic disrupting the body's natural balance of microorganisms.

Q: Does Levo 500 cause changes to the sense of taste or smell?

Changes to the sense of taste, known as dysgeusia, are listed in official product information as an uncommon side effect. However, changes to the sense of smell are not consistently or commonly documented as an adverse reaction in the same regulatory sources.

Q: What is the evidence supporting Levo 500 use for skin infections?

Clinical trial evidence reviewed by regulatory bodies includes studies on uncomplicated skin and skin structure infections. These studies examine outcomes like the elimination of the causative bacteria and clinical response, and relevant findings are available regarding the elimination of the causative bacteria and clinical response for these conditions.

How should Levo 500 be stored and disposed of?

How to Store and Dispose of Levofloxacin 500 mg Tablets

The storage of Levofloxacin 500 mg tablets must adhere strictly to regulatory conditions to maintain stability and effectiveness.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection	Must be protected from freezing, excessive heat, moisture, and light.
Container	Keep the tablets in their closed container.
Child Safety	Store the medicine out of the sight and reach of children.

Disposal Instructions

Outdated or unused Levofloxacin tablets must be properly discarded. Regulatory guidelines instruct patients to consult a pharmacist or healthcare professional for instructions on disposal.

It is strictly prohibited to dispose of the tablets by throwing them into wastewater (such as flushing them down a toilet) or placing them in general household trash.

Levo 500